{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Pruritus was reported monthly by pts using a 0 (no itching) to 100 (unbearable itching) mm visual analog scale (VAS). Pts were considered to have significant pruritus if the baseline VAS score was ≥ 30 mm. Clinically meaningful reduction in pruritus was defined as a decrease in VAS score of ≥ 30 mm or a score of 0 for at least 2 consecutive cycles.","groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"OG000","title":"Romidepsin"}],"paramType":"NUMBER","populationDescription":"Patients meeting definition of moderate to severe pruritus on VAS (i.e., had a VAS of \\>=30 mm)","reportingStatus":"POSTED","timeFrame":"Up to 10 months","title":"Decrease in Pruritus Visual Analogue Scale (VAS) Score of ≥30 mm or a Score of 0 for at Least 2 Consecutive Cycles.","type":"SECONDARY","unitOfMeasure":"participants"}